A Phase 2 interventional study of RX-10045 and Placebo in Dry Eye Syndrome, sponsored by Resolvyx Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-09-24.
Sponsored by Resolvyx Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment
The purpose of this study is to compare the safety and efficacy of RX-10045 to placebo for the treatment of the signs and symptoms of dry eye.
1,292 studies on the registry are indexed under Dry Eye Syndromes; 191 are open to participants now.
This study's enrollment of 232 is above the median of 60 across 1,077 interventional studies indexed under Dry Eye Syndromes.
Browse Dry Eye Syndromes studies →Resolvyx Pharmaceuticals, Inc is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Placebo
Drug: RX-10045
RX-10045 eye drop
Placebo eye drop
Corneal fluorescein staining and integrated subject diary data
Time frame: 28 days
Changes in dry eye signs and symptoms
Time frame: 28 days
This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Resolvyx Pharmaceuticals, Inc